ERBB2 and breast carcinoma: The remaining discordant breast cancer case had tissue NGS amplification and HER2 copy number >4, but given the lack of overexpression and HER2/CEP17 ratio <2.0, was negative per guidelines for patients falling into Group 4 with the comment “it is uncertain whether patients [...] benefit from HER2 targeted therapy in the absence of protein overexpression”.